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Abstract
Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are
ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The
capacity of the LRAs to perturb the viral reservoir present in distinct subpopulations of cells
is currently unknown. Here, using a new RNA FISH/flow ex vivo viral reactivation assay, we
performed a comprehensive assessment of the viral reactivation capacity of different fami-
lies of LRAs, and their combinations, in different CD4+ T cell subsets. We observed that a
median of 16.28% of the whole HIV-reservoir induced HIV-1 transcripts after viral reactiva-
tion, but only 10.10% of these HIV-1 RNA+ cells produced the viral protein p24. Moreover,
none of the LRAs were powerful enough to reactivate HIV-1 transcription in all CD4+ T cell
subpopulations. For instance, the combination of Romidepsin and Ingenol was identified as
the best combination of drugs at increasing the proportion of HIV-1 RNA+ cells, in most, but
not all, CD4+ T cell subsets. Importantly, memory stem cells were identified as highly resis-
tant to HIV-1 reactivation, and only the combination of Panobinostat and Bryostatin-1 signifi-
cantly increased the number of cells transcribing HIV within this subset. Overall, our results
validate the use of the RNA FISH/flow technique to assess the potency of LRAs among dif-
ferent CD4+ T cell subsets, manifest the intrinsic differences between cells that encompass
the latent HIV reservoir, and highlight the difficulty to significantly impact the latent infection
with the currently available drugs. Thus, our results have important implications for the ratio-
nal design of therapies aimed at reversing HIV latency from diverse cellular reservoirs.
Author summary
HIV infection is an incurable disease. Despite antiretroviral therapy, a pool of cells with
HIV in a latent state persists and precludes fully eradication of the viral infection. The
cells that contain this latent viral reservoir are very diverse, and therefore different
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therapeutic strategies would be necessary to target and eliminate all infected cells. Latency
Reversal Agents (LRAs) are compounds able to awake the latent virus from its dormant
state with the purpose of making infected cells visible to the immune system. But the abil-
ity of the LRAs to target different cell types containing HIV is currently unknown. Here,
using a novel methodology that interrogates individual cells, we found that current LRAs
do not impact equally all infected cells. In fact, certain types of memory lymphocytes, rec-
ognized to harbor latent HIV for decades, are not fully impacted by most of the LRAs
tested. Our study highlights the difficulty to cure HIV with the currently available LRAs.
Different therapeutic approaches aimed at reversing HIV latency from diverse cellular res-
ervoirs are needed to reduce HIV persistence.
Introduction
Current antiretroviral therapy (ART) is extremely effective at suppressing HIV viremia below
the limit of detection of standard clinical assays and substantially reduces the morbidity and
mortality associated with the HIV-1 infection. However, ART is unable to fully eliminate and
eradicate HIV from the human body [1,2]. This is mainly due to the presence of latently HIV-
infected cells generated in the early stages of the infection that are not susceptible to current
antiretroviral drugs [3]. The development of new clinical strategies targeting the persistent
virus may lead to a long-term drug-free remission of HIV infection, which currently represents
a high priority for HIV-1 research [4,5].
Over the last years, the “kick and kill” therapeutic strategy has been pursued as an approach
for eliminating HIV; latently HIV-infected cells are pharmacologically forced to induce HIV
transcription with the hope that viral reactivated cells will be cleared by virus-induced cyto-
pathic effects or by the immune system [6–8]. In this regard, drug discovery efforts have iden-
tified several latency reversal agents (LRAs), compounds that can efficiently induce HIV
expression. Vorinostat, Romidepsin and Panobinostat belong to the histone deacetylase inhibi-
tor (HDACi) family. HDACi can suppress the histone deacetylases enzymes that enzymatically
remove the acetyl group from histones, and as a consequence they induce gene expression.
Importantly, HDACi successfully reactivated latent HIV in the first-in-human clinical trials
[9–11]. Further, Disulfiram, a drug previously used to treat alcoholism, has been shown to
increase HIV transcription in a subgroup of ART-suppressed patients after in vivo administra-
tion [12]. However, so far, none of the current LRAs tested in patients have proven to be effec-
tive at decreasing the size of the latent HIV reservoir. Other compounds, not yet tested in
humans, have shown promising results ex vivo. In this sense, the PKC (protein kinase C) ago-
nists Ingenol [13] and Bryostatin-1 [14] are involved in the PKC pathway, which plays an
important role in cellular latency and reactivation of HIV via NF-κB (nuclear factor kappa-
light-chain-enhancer of activated B cells) signaling and via P-TEFb (positive transcription
elongation factor b). The bromo and extra terminal (BET) bromodomain inhibitor JQ1 [15]
also reactivates HIV by its effect through the P-TEFb. Lastly, a novel family of LRAs has been
identified; the benzotriazoles successfully increase viral transcription dependent on STAT5
phosphorylation [16].
An important issue for current and future clinical trials aimed at curing HIV infection
through the administration of LRAs is to determine how effective these compounds are in
fully reactivating the virus from all latently-infected CD4+ T cell subpopulations. The CD4+ T
cell pool encompasses a heterogeneous population of cells defined by the differential expres-
sion of cell surface receptors associated with different stages of cell maturation, activation and
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differentiation [17,18]. These CD4+ T cell subpopulations include naive cells (TNA), stem cell
memory (TSCM), central memory (TCM), transitional memory (TTM), effector memory (TEM)
and terminally differentiated cells (TTD). As HIV transcription level and infection frequency
differ by cell type [19–22], the characterization of the responses of the different CD4+ T cell
subpopulations to pharmacological HIV reactivation will guide us on the design of more effec-
tive therapies aimed at reducing HIV persistence.
Currently, the most used assay for measuring the impact of LRAs on HIV reactivation is
the quantification of intracellular HIV-1 RNA by conventional quantitative PCR assays
[11,23–25]. Several other methodologies, as the quantitative viral outgrowth assay (qVOA),
Tat/rev induced limiting dilution assay (TILDA) or the quantification of viral DNA, have also
been used to characterize the action of different LRAs in patient samples [26–28]. Recently, a
new assay that detects HIV reactivation using a dual staining protocol of the viral protein p24
has been described [29]. However, due to the low number of cells responding to the LRAs in
patients, current assays require the use of large quantities of cells to accurately measure viral
transcription. Furthermore, the detailed characterization of the different cell subsets respond-
ing to LRAs has been scarce so far, since it requires the previous isolation of the specific cell
subsets under evaluation. In order to overcome these limitations, we have recently reported a
novel RNA FISH/flow method, which is based on the quantification of viral RNA by flow
cytometry allowing the quantification and phenotyping of cells expressing HIV-1 RNA mole-
cules at the single cell level [30,31]. Importantly, HIV-1 RNA expressed in different subpopula-
tions of CD4+ T cells can be successfully determined by this novel system.
Here, we have used and validated the RNA FISH/flow assay as a novel methodology suitable
to evaluate compounds that can be pursued to reactivate the latent virus in patient-derived
HIV infected cells. Using this methodology, we have characterized the specific responses of
different CD4+ T cell subpopulations to the action of several LRAs families and their combina-
tions. Overall, in CD4+ T cells we found that, on average, 16.28% of cells containing HIV-1
DNA were able to reactivate HIV with the most potent LRAs tested. From these cells, only a
small fraction (~10%) produced the viral protein p24. Furthermore, we observed heteroge-
neous responses of specific cell differentiation phenotypes to these compounds, and we identi-
fied the combination of Romidepsin plus Ingenol as the most effective drug combination to
efficiently increase HIV transcription and p24 production in most CD4+ T cell subsets. These
findings highlight the difficulty to find LRAs able to reactivate HIV present in all cellular reser-
voirs; an essential requirement for the “kick and kill” therapeutic strategy to successfully
impact persisting HIV in infected patients.
Results
HIV reactivation kinetics with single and combined latency reversal agents
in the latently infected cell line J-Lat
In order to evaluate the potency and timing of the different LRAs at reactivating latent HIV,
we initially tested them in the latently infected cell line J-Lat (clone 10.6), which contains inte-
grated but transcriptionally competent HIV proviruses that express the green fluorescence
protein (GFP) after viral reactivation. We evaluated the following families of LRAs: HDACi
(Panobinostat and Romidepsin), PKC agonists (Ingenol and Bryostatin-1) and a bromodo-
main inhibitor (JQ1). Drugs were used at concentrations previously shown to be effective at
reversing HIV latency [23,32,33]. To best measure HIV reactivation and in order to avoid the
loss of GFP signal due to the cell death of highly viral-reactivated cells, we treated cells with the
pan-caspase inhibitor Q-VD-OPh before the addition of the compounds. Previous results
showed that J-Lat cells and CD4+ T cells from patients stimulated with Panobinostat expressed
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higher levels of GFP and HIV-1 RNA, respectively, when cells were simultaneously treated
with the pan-caspase inhibitor (S1A and S1B Fig).
In J-Lat cells, after incubation with single LRAs and a detailed monitoring of the viral
dynamics, we observed that viral reactivation for most LRAs tested reached its maximum or a
plateau after 20-24h of drug exposure, except for JQ1 that gradually increased the expression
of GFP during the entire incubation period (50h). Romidepsin induced the highest reactiva-
tion level (24% of GFP+ cells), followed by Ingenol and Panobinostat (20 and 15% of GFP+
cells, respectively) (Fig 1). In this model of latent infection, Bryostatin-1 did not induce a sig-
nificant viral reactivation. In addition, we analyzed the effect that the combination of different
families of LRAs had on HIV transcription. Romidepsin plus Ingenol was the most potent
combination of LRAs, reaching values of 35% of GFP+ cells. Moreover, we also observed an
additive effect at reactivating HIV when Ingenol was combined with Panobinostat and with
Fig 1. HIV reactivation kinetics in the latently infected cell line J-Lat. J-Lat cells were incubated for 50h with
medium (R10), single LRAs or the combination of different families of these compounds; Panobinostat (PNB, 30 nM),
Romidepsin (RMD, 40 nM), Ingenol (ING, 100 nM), Bryostatin-1 (BRY-1, 10 nM) and JQ1 (1 uM). Percentage of
GFP+ (in green) and Annexin V+ (in red) cells was monitored each hour using the IncuCyte ZOOM live cell imaging
system (Essen Bioscience). Dashed lines show the effect at 22h for the single drugs Panobinostat, Romidepsin and JQ1
(in yellow) and for Ingenol and Bryostatin-1 (in blue). Dotted lines represent 22h.
https://doi.org/10.1371/journal.ppat.1007991.g001
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JQ1 (27 and 28% of GFP+ cells, respectively). Importantly, in our experimental system, we
observed that after 20-24h of drug treatment neither the single compounds nor their combina-
tions induced more than 12% of cell apoptosis in J-Lat cells (Fig 1). Next, we tested the ability
of the RNA FISH/flow assay to detect HIV-1 RNA and the viral protein p24 after the adminis-
tration of LRAs. J-Lat cells were cultured with Romidepsin or with Romidepsin plus Ingenol
for 22h (S2A Fig). We observed that, as previously shown [30,34], the RNA FISH/flow tech-
nology is able to distinguish two HIV-1 RNA positive populations: single HIV-1 RNA+ cells,
and cells expressing both HIV-1 RNA and p24. Importantly, the population of cells expressing
HIV-1 RNA and p24 was highly abundant (~90% of cells) when the culture was treated with
the combination of the 2 LRAs, compared to single LRAs (~50% of cells) (S2A Fig). These val-
ues corresponded to percentages of GFP+ and HIV-1 RNA+ cells of 58.1% for Romidepsin
alone and 90.2% for Romidepsin plus Ingenol (S2B Fig). Differences in the proportion of posi-
tive cells between these results and those provided in Fig 1 are more likely due to the read out
and the normalization method used to quantify viral reactivation with the different assays.
Overall, we determined 22h as the more adequate timing to observe viral reactivation with all
tested LRAs.
Detection of HIV-1 RNA after viral reactivation with single and combined
LRAs in primary CD4+ T cells
First, we measured drug toxicity induced by the addition of LRAs to primary CD4+ T cells.
Early apoptosis, late apoptosis and cell death were identified as shown in S3A Fig. Overall,
LRAs induced a maximum median of 11.34% of cell death (condition Romidepsin plus Inge-
nol) when drugs were added for 22h to previously-isolated CD4+ T cells obtained from unin-
fected donors (S3C Fig). However, under our experimental conditions, using the pan-caspase
inhibitor Q-VD-OPh, no more than 3.04% of cell death was quantified (S3B Fig). Moreover,
in CD4+ T cell subsets we observed that TTD and TEM cells, the more differentiated cell subsets,
were more susceptible to cell death, especially when treated with the combination of Romidep-
sin and Ingenol (~10% dead cells, S3D Fig). On the contrary, TCM and TNA cells showed the
lowest percentages of cell death when treated with different LRAs (maximum 2–3% of cell
death) (S3D Fig). Drug toxicities in the absence of the caspase inhibitor are shown in S3E Fig.
Of note, drug toxicity that remains despite Q-VD-OPh treatment might be caused by other
cell death mechanisms, such as pyroptosis or cell necrosis [35]. Overall, Romidepsin plus Inge-
nol was the most toxic combination of drugs in all CD4+ T cell subpopulations. Nevertheless,
even in this condition drug toxicity still remained relatively low after 22h of cell culture, and
thus it is very unlikely that drug toxicity might preclude the interpretation of the viral reactiva-
tion assays.
Then, we tested the potential of LRAs to reactivate latently HIV-infected cells in fresh sam-
ples from 9 ART-treated individuals. At least 6x106 isolated CD4+ T cells were cultured per
condition during 22h, and a total of 13 conditions were set up for each patient. After viral reac-
tivation, cells were subjected to the RNA FISH/flow assay in order to evaluate the frequency of
cells that responded to the action of LRAs and were able to reactivate the latent provirus. The
sensitivity of this assay at detecting HIV-1 RNA+ cells was previously established at 10
HIV-RNA+ cells per million cells [30]. The representative flow cytometry gating strategy used
to identify HIV expression and production of the viral protein p24 in different subpopulations
of CD4+ T cells is shown in S4A Fig. Overall, most tested LRAs and the combination of differ-
ent families of LRAs significantly increased the frequency of cells expressing HIV-1 RNA in
most patients compared to the non-reactivated control (p<0.05) (Fig 2A). For single LRAs, we
observed that Ingenol, Romidepsin and Panobinostat increased the proportion of HIV-1 RNA
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Fig 2. Detection of cells expressing HIV-1 RNA after viral reactivation with different LRAs. Freshly isolated CD4+ T cells from 9 ART-suppressed HIV-infected
individuals were reactivated with different LRAs for 22h and subjected to the RNA FISH/flow protocol for detection of HIV transcripts. Drug concentrations were as
follows: 40 nM Romidepsin (RMD), 30 nM Panobinostat (PNB), 1 μM JQ1, 100 nM Ingenol (ING), 10 nM Bryostatin-1 (BRY-1), 81 nM PMA plus 1 μM Ionomycin
(IONO) or media alone. A. Proportion of cells expressing HIV-1 RNA in CD4+ T cells for each condition normalized to the medium control from individual patients are
shown. Medians and min and max ranks are represented and statistical comparisons with the control medium were performed using the Wilcoxon test. �p<0.05,
��p<0.01. B. Percentage of patients showing synergistic, antagonistic or additive effects (Bliss independence model) on HIV reactivation are shown as individual ring
graphs for each combination of different LRA families studied. C. Proportion of HIV-transcribing cells relative to the positive control PMA/Ionomycin. Pies for
individual patients normalized to the positive control and median values for all patients are represented in a box and whisker plot graph. HIV-1 RNA+ and HIV-1 RNA-
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expressing cells to higher levels (median values of 67 for Ingenol, 66 for Romidepsin and 48
for Panobinostat, expressed as cells per million, p = 0.0039, 0.0039 and 0.054, respectively,
compared to the media control) than Bryostatin-1 or JQ1 (median values of 19 for Bryostatin-
1 and 33 for JQ1, p = 0.015 and 0.039, respectively). However, only Ingenol was effective at
reactivating HIV in all tested patients, compared to Romidepsin (8 out of 9 patients) and Pano-
binostat (7 out of 9 patients). For the combinations of LRAs, we observed that Romidepsin
plus Ingenol promoted the highest induction of cells expressing HIV-1 RNA in all tested
patients (p = 0.0039, fold change (FC) = 3.50, compared to the negative control) (Fig 2A). Of
note, in this specific condition the proportion of HIV-1 RNA+ cells was even higher than the
resulting proportion of cells cultured with the positive control of PMA and Ionomycin
(median values of 180 for Romidepsin plus Ingenol and 64 for PMA and Ionomycin,
p = 0.0078). We also observed that the combination of JQ1 with Ingenol induced a high pro-
portion of cells expressing HIV-1 RNA (median value of 78, p = 0.0039) in 8 out 9 patients
(Fig 2A). Furthermore, we calculated the synergistic, additive or antagonistic effects of the dif-
ferent combinations of LRAs using the Bliss independence Model [33,36]. We observed that
Romidepsin and Ingenol presented the highest synergistic effect in 45% of the patients ana-
lyzed, while the other drug combinations promoted drug synergy in 22% of the patients at the
most (Fig 2B). Moreover, it should be noted that the combination of Panobinostat and Ingenol
induced an important antagonistic effect in 89% of the patients tested (Fig 2B). The synergistic
effects between the different families of the LRAs in the individual patients are depicted in S4B
Fig. Next, we normalized the values of RNA-expressing cells to the positive control, PMA and
Ionomycin. Supporting the results showed in Fig 2B, we observed that Ingenol and Romidep-
sin were equally potent at reactivating cells expressing HIV than the positive control in 7 out
of 9 and in 5 out of 9 patients, respectively. A more modest effect was observed for Panobino-
stat, Bryostatin-1 and JQ1 alone (Fig 2C). The best drug combinations again were Romidepsin
plus Ingenol and JQ1 plus Ingenol, which increased the proportion of HIV-1 RNA expressing
cells at levels comparable to the positive control in 9 out of 9, and 6 out of 9 patients, respec-
tively. In addition, in patients #1, 3, 6 and 8, Panobinostat only reactivated at most half of the
values obtained with the positive control. In the same patients, Ingenol was equally potent
than the positive control; however, the combination of both drugs decreased the proportion of
cells expressing HIV-1 RNA compared with the single drug Ingenol, compatible with an antag-
onist effect when both compounds are combined (Fig 2C). Besides, since we have recently
described that CD4+ T cells expressing CD32dim are enriched in HIV transcripts in vivo, and
that viral infection upregulates this marker [30,37], we analyzed the expression of CD32dim in
viral-reactivated cells using different LRAs. We observed that CD32dim was consistently upre-
gulated after the pharmacological reactivation of HIV (S4C Fig).
Detection of HIV protein p24 after viral reactivation with LRAs in primary
CD4+ T cells from HIV-infected patients
First, we determined the sensitivity of the assay at detecting HIV-1 RNA+ and p24+ cells. Pri-
mary ex vivo infected cells were spiked into uninfected cells at different ratios and the mixture
fractions are shown in orange and blue, respectively. D. Fraction of the HIV-reservoir susceptible to HIV reactivation after LRA treatment in CD4+ T cells from 9 ART-
suppressed patients. Lower pies show the proportion of reactivated and non-reactivated cells. Upper pies show the fraction of reactivated cells after treatment with each
compound depicted in the adjacent legend. We next calculated the percentage of the HIV-transcriptionally active viral reservoir after exogenous reactivation with the
LRAs. We observed that between 3 and 31% (median value of 16.28%) of the total cells that encompass the viral reservoir (measured as the number of cells containing
proviral DNA) were capable of transcribing HIV-1 RNA after viral reactivation (Fig 2D). The potency of each LRAs and their combinations in each individual patient is
also shown in Fig 2D. Thus, while in general only a fraction of cells harboring HIV-1 DNA can be reactivated by current available LRAs, differences in terms of strength
and consistency of this viral reactivation are observed in the whole population of CD4+ T cells from different ART-treated individuals.
https://doi.org/10.1371/journal.ppat.1007991.g002
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was then subjected to the RNA FISH/flow protocol. We observed that dual expression of HIV-
1 RNA and p24 determined by the experimental curve showed consistency with the predicted
curve at all of the dilutions tested, establishing a limit of detection of 10–20 positive events per
million cells (S2C Fig). Next, in order to determine whether LRAs and their different combi-
nations were also capable of inducing the expression of the viral protein p24, we performed
the RNA FISH/flow protocol with the simultaneous staining of intracellular p24. We analyzed
the percentage of cells transcribing HIV-1 RNA that were also able to produce p24. As shown
in Fig 3A, cells expressing p24 significantly increased after the addition of all LRAs but two,
Bryostatin-1 and JQ1. Ingenol, Romidepsin and Panobinostat were the most potent LRAs at
inducing the translation of viral transcripts (median values of 5.62, 4.17 and 3.64%, respec-
tively). The combination of LRAs produced significant proportions of cells expressing p24,
except when JQ1 was combined with Bryostatin-1 (median value of 0.99%). The positive con-
trol PMA and Ionomycin was the most potent drug (median value of 8.33%), followed by the
combination of Ingenol and Romidepsin (median value of 7.14%, Fig 3A). However, in gen-
eral, we did not detect more than 10% of HIV-1 RNA+ cells expressing p24. Of note, the com-
bination of JQ1 and Ingenol produced high levels of cells transcribing HIV-1 RNA, however
this combination only induced p24 in a modest proportion of cells (3.23%). Moreover, no syn-
ergies were detected for the production of the viral protein p24 in any of the combinations
Fig 3. Proportion of CD4+ T cells expressing the viral protein p24 after viral reactivation with different LRAs. A. The proportion of HIV-transcribing CD4+ T cells
that simultaneously produce the viral protein p24 is shown. Comparisons with the control medium were performed using the Wilcoxon test. �p<0.05, ��p<0.01. B.
Calculation of synergistic, antagonistic or additive effect after the combination of LRAs using the Bliss independence model. White symbols correspond to patients in
which production of p24 was not detected. Medians and min to max ranks are represented in panels A and B. C. Normalization of the percentage of HIV-transcribing
cells expressing p24 relative to PMA/Ionomycin. Pies for individual patients and median values for all patients are represented in a box and whisker plot graph. Fractions
of HIV-1 RNA+ cells expressing p24 and lacking the expression of p24 are shown in orange and blue, respectively.
https://doi.org/10.1371/journal.ppat.1007991.g003
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tested and, in concordance with the transcription data, we determined an antagonistic effect in
the majority of patients when the combination of Panobinostat and Ingenol was used for viral
reactivation (Fig 3B). Next, we normalized the proportion of p24+ cells to the maximum values
obtained with the positive control (Fig 3C). In agreement with the results described in Fig 2C,
we observed a negative effect when we combined Panobinostat and Ingenol (i.e patients #1
and 3) (Fig 3C). Furthermore, we observed a statistical significant correlation between the pro-
portion of HIV-1 RNA+ cells and the percentage of the cells that are able to produce p24 after
different LRA treatments (p<0.0001) (S4D Fig).
Taken together, individual LRAs have different capabilities of increasing the proportions of
HIV-1 RNA and p24-expressing CD4+ T cells. In general, there was an agreement between the
frequency of cells expressing HIV-1 RNA and p24, but some disconnection was observed for
some LRAs; Romidepsin and Ingenol was the combination inducing the larger proportion of
RNA-expressing cells, however PMA and Ionomycin outperformed them in their ability to
induce p24-expressing cells. This is in agreement with previous reported results that deter-
mined that the positive control (anti-CD3/CD28 antibody-coated beads) was able to induce
higher levels of multiply spliced Tat-Rev HIV-1 transcripts compared to unspliced HIV-1
RNA. On the contrary, Romidepsin induced higher levels of unspliced HIV-RNA compared to
Tat-Rev transcripts [38]. Moreover, we detected an antagonist effect, in both HIV-1 RNA+ and
p24+ cells, when Panobinostat and Ingenol were combined.
Heterogeneous responses to LRAs of different CD4+ T cell subpopulations
Next, we focused our investigations on the capabilities of LRAs at reactivating HIV in different
CD4+ T cell subpopulations. To do so, we isolated fresh CD4+ T cells from ART-treated
patients and after LRA addition, transcription of HIV was measured by the RNA FISH/flow
assay. Firstly, we assessed the impact of the different LRAs on the phenotypic markers used to
identify the different CD4+ T cell subpopulations. We observe that the proportions of the dif-
ferent subsets were, in general, well maintained after treatment with the different drugs. Only
very small differences were detected in some conditions (S5A Fig). We consider that these
changes are negligible and it should not significantly impact the proportion of virally-reacti-
vated cells. Moreover, we observed that Romidepsin increased the proportion of memory cells
transcribing HIV-1 RNA compared to the control, including central memory (TCM) (FC =
2.33, p = 0.0039), effector memory (TEM) (FC = 4.24, p = 0.007) and transitional memory
(TTM) (FC = 4.06, p = 0.046) cells, and also naïve cells (TNA) (FC = 1.72, p = 0.0078) (Fig 4A).
However, Panobinostat was less potent at inducing HIV-1 RNA+ cells in TTM; indeed, we
observed the highest effect in TCM (FC = 2.11, p = 0.0039) and a modest effect in TEM and TNA
(FC = 2.32, p = 0.031 and FC = 1.27, p = 0.0156, respectively). Although significant, JQ1
induced a modest frequency of cells transcribing HIV-1 RNA in the majority of subsets ana-
lyzed, except for TSCM. Moreover, Ingenol preferentially reactivated TCM (FC = 4.05, p =
0.0039) and TTM (FC = 5.27, p = 0.0156) in most patients, which reached statistical signifi-
cance. Although not significant, Ingenol also reactivated HIV in TEM cells in 4 out of 9
patients. Finally, Bryostatin-1 reactivated very modestly some subsets, including TNA, TTD and
TCM (FC = 1.49, p = 0.0156; FC = 1.94, p = 0.031; and FC = 1.22, p = 0.0156, respectively) (Fig
4A). A summary heatmap for the effect of single drugs is shown in S6A Fig. In addition, we
analyzed the data stratified by CD4+ T cell subsets (Fig 4B). In general, TCM and TNA subpopu-
lations were successfully reactivated by almost all tested drugs. TCM and TTM were more effi-
ciently reactivated by Ingenol, while TEM cells transcribed more HIV when cells were treated
with Romidepsin. Moreover, HIV transcription was induced in TNA cells more robustly after
the addition of Ingenol and Romidepsin, and in TSCM after Ingenol treatment. TTD cells
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showed a distinct pattern of reactivation, since Ingenol, Bryostatin-1 and JQ1 were the only
single LRAs that increased the proportion of cells expressing HIV in this specific subset (Fig
4B). Importantly, the combination of Romidepsin and Ingenol induced the largest proportion
of cells transcribing HIV in most CD4+ T subsets, outperforming most LRAs and their combi-
nations (FC = 3.44, p = 0.0039 for TCM; FC = 6.72, p = 0.0078 for TTM; FC = 6.96, p = 0.0156
for TEM; FC = 7.61, p = 0.0078 for TTD; FC = 2.54, p = 0.0039 for TNA; and FC = 2.61, p = 0.062
for TSCM) (Fig 4B). However, within the TSCM subset only the combination of Panobinostat
plus Bryostatin-1 was able to induce a significant increase of HIV-1 RNA+ cells (Fig 4B). A
summary heatmap on the effect of drug combinations in the different CD4+ T cell subsets is
shown in S6B Fig. Finally, we calculated the interactions between each drug combination in
the individual patients (S6C Fig). In the majority of patients, the combination of Romidepsin
and Ingenol was synergistic in memory cells (TCM 45%, TTM 67%, TEM 44.5% and TTD 67%)
(Figs 4C and S6C). However, the combination of drugs that induced significant synergy in
TNA cells was JQ1 plus Ingenol (56%), and in TSCM Panobinostat plus Bryostatin-1 (44%). As
we already observed in the total CD4+ T cell population, the combination of Panobinostat and
Ingenol produced an antagonistic effect in memory cells (TCM 89%, TEM 67%, TTM 56%, TSCM
67% and TTD 67%). However, for the TTM subset the combination of JQ1 and Ingenol was also
antagonistic in most patients (78%) (Figs 4C and S6C). The reactivation induced by the posi-
tive control, PMA and Ionomycin, was not evaluated in CD4+T cells subsets due to the diffi-
culty to gate accurately the different CD4+ T subpopulations.
Next, we investigated not only the capabilities of LRAs to induce HIV transcription, but
also to generate the viral protein p24 expression in the different CD4+ T cell subsets. We
observed that the combination of Romidepsin and Ingenol was able to induce a substantial
increase of cells producing p24 in TCM cells in most patients (Fig 4D), although it did not
induce a synergistic effect (S6D Fig). Of note, for all remaining cell subsets, we were not able
to detect significant number of cells expressing p24. The low percentage of cells expressing p24
and the low absolute number of HIV-1 RNA+ cells detected in the remaining subsets may
explain this observation.
Overall, different CD4+ T cells subsets have different susceptibilities to LRAs and their com-
binations, but in general, we found that Romidepsin plus Ingenol was the most potent combi-
nation of LRAs, increasing significantly the proportion of HIV+ cells and producing a
synergistic effect compared to the individual drugs. We also observed that TCM and TNA sub-
populations presented broader susceptibility to the different families of LRAs, despite TTD
and, specially, TSCM were more resistant to HIV reactivation. Furthermore, we determined a
robust antagonistic effect when Panobinostat and Ingenol were used in combination in most
subsets analyzed as we observed in the whole population of CD4+ T cells.
Discussion
The elimination of the latently infected cell reservoir is believed to be the most important
requirement to definitively eradicate HIV from the human body. Currently, therapeutic
Fig 4. Proportion of cells expressing HIV-1 RNA and p24 after viral reactivation in different CD4+ T cell subpopulations. A. Proportion of cells
transcribing HIV-1 RNA after viral reactivation with single LRAs in the following populations: TNA, TSCM, TCM, TTM, TEM and TTD. Medians are shown.
B. Proportion of HIV-1+ cells per million cells in each CD4+ T cell subpopulation with all tested drugs and their combinations. C. Proportion of patients
showing synergistic, antagonistic or additive effects (Bliss independence model) after HIV reactivation with combinations of LRAs are shown for each
CD4+ T cell subset. Percentage of patients responding to LRAs interactions are shown for each cell subset. D. Proportion of HIV-1 RNA+ TCM cells
expressing the viral protein p24. Black asterisks denote statistical significance compared with the negative control (media) using a Wilcoxon test. Red
asterisks denote statistical significance compared with the combination of Romidepsin plus Ingenol using a Friedman test followed by Dunn’s post hoc
tests. Medians and min to max ranks are represented in panels B and D. �p<0.05, ��p<0.01.
https://doi.org/10.1371/journal.ppat.1007991.g004
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strategies named “kick and kill” are focused on the reactivation of these latent proviruses in
ART-treated individuals using pharmacological compounds, the so-called LRAs. The ultimate
goal of LRAs is to render infected cells susceptible to immune responses or to induce cell death
by viral cytopathic effects. However, the impact of the drugs used to “kick” the virus on the
subpopulations of cells that encompass the latent HIV reservoir is currently unknown. Impor-
tantly, clinical studies designed to perturb the latent HIV reservoir using LRAs have demon-
strated an important increase in HIV transcription [10,11]. However, no effect was observed
on the reduction of the size of the HIV reservoir following LRAs treatment. Since cell suscepti-
bility to reactivating stimuli is the result of a complex interplay of individual viral and host fac-
tors, the inability of current drugs to reactivate latent HIV present in specific subsets of long-
lived cells might help to explain the recent failures of clinical trials.
In this study, we investigated for the first time the impact of several families of LRAs, such
as the HDACi (Romidepsin and Panobinostat), the PKC agonists (Ingenol and Bryostatin-1),
and the bromodomain inhibitor JQ1, on their ability to induce viral transcripts in freshly-iso-
lated CD4+ T cells from aviremic ART-treated HIV-infected individuals. Using a novel flow
cytometry technique, the RNA FISH/flow method, we studied the reactivation of HIV from
cellular reservoirs. Although we do not detect all fully replication-competent viruses, positive
cells detected using this method are able to produce elongated HIV-1 RNA upon LRA treat-
ment, and in some cases, to produce the viral protein p24. Importantly, the frequency of blood
cells induced to transcribe HIV-1 RNA has been previously correlated with the frequency of
cells induced to express infectious virus [39]. Therefore, detection of HIV-1 RNAs have biolog-
ical importance.
Here, we observed that the fraction of the total HIV-reservoir that can be reactivated by the
tested LRAs varied between patients, ranging from 3 to 31%. These results concur with Banga
et al. [25], which indicated that only a fraction (�2.6%) of HIV-1 proviruses were reactivated
to produce virions, supporting also results from Cillo et al. [24]. This low percentage of viral
reactivation might be explained, in part, by the fact that most of HIV-1 DNA present in ART-
treated patients contains fatal mutations; only 2–10% of proviruses are considered intact, and
therefore, more likely to produce full length HIV-1 RNA transcripts [40,41]. Moreover,
between 60–80% of the proviruses might present deletions in the gag-pol region [40], preclud-
ing the detection of viral transcription by the RNA FISH/flow method. It should be note that
we are using fresh CD4+ T cells from a single blood draw, and therefore it is uncertain if simi-
lar results will be obtained from blood collected at different time points. We speculate that the
results using LRAs with cells collected at different time points will mainly depend on the size
and stability of the transcriptionally-inducible HIV-1 reservoir. Of note, we have not measure
the half-live of the transcriptionally-inducible HIV reservoir in ART-treated patients, but as
demonstrated for other reservoir measurements, the stability will be more likely dependent on
the individual patient; i.e. the half-live of the replication competent HIV reservoir is approxi-
mately 44 months (if measured as IUPM or IDPA) [40], but other factors, such as clonal
expansion, ongoing viral replication, and redistribution of infected cells from lymphoid tissue,
will significantly affect its longitudinal stability [42]. Additionally, the intrinsic stability of the
different cell subsets that contain the inducible HIV-1, might also account for the variation in
the level of viral reactivation.
For all tested drugs we observed a significant increase in the proportion of HIV-1 RNA+
cells, but some LRAs were especially potent at increasing their frequency. As single drugs, and
in concordance with our in vitro data generated in the J-Lat cell line, Romidepsin and Ingenol
induced the highest frequency of cells expressing HIV-1 RNA in nearly all samples. These find-
ings are in agreement with previous reports; Pandelo´ et al. showed that Ingenol disrupted HIV
latency at higher levels compared to PMA or Vorinostat, both in latency cell models and in
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infected primary resting cells [13], while Wei et al. demonstrated that Romidepsin induced an
important increase in HIV-1 transcription compared to Vorinostat in both total memory and
resting cells from HIV infected patients [43]. Moreover, we observed that JQ1 and Bryostatin-
1 reactivated HIV-1 very poorly. In contrast to our results, it has been previously showed that
in resting CD4+ T cells from HIV-patients only Bryostatin-1 induced an increment in the pro-
duction of RNA compared to the HDAC inhibitors Romidepsin, Panobinostat and Vorinostat,
and the bromodomain inhibitor JQ1 [23]. In the study, the authors used qPCR to measure
viral reactivation, thus a potent induction of HIV in a limited number of cells might help to
explain the discrepancy between both studies. Another study from Jiang et al. [44], described a
synergistic effect when JQ1 plus Ingenol were combined, but in our work we observed an
antagonistic effect in the 56% of the patients. The fact that different Ingenol molecules can be
used for viral reactivation studies, the different methods used to detect viral reactivation, and
the discrepancies observed between cell lines and primary CD4+ T cells in viral reactivation
protocols [32], might explain this contradictory result.
Furthermore, we characterized the responses of each CD4+ T subpopulation to different
LRAs. These investigations have rarely been performed before, mainly due to the difficulty to
obtain enough cells from each CD4+ T cell subset to comprehensively quantify viral reactiva-
tion. In order to overcome this limitation, we used the novel RNA FISH/flow methodology
that allows the simultaneous detection of HIV-1 RNA transcripts and the viral protein p24 at
the single cell level without the need to previously isolate the fraction of cells being evaluated
[30]. In general, each LRA was impacting differently the CD4+ T cell subpopulations; even
drugs belonging to the same family had a differential effect on the same cell subsets. For
instance, Panobinostat successfully reactivated HIV in TCM cells, whereas Romidepsin was
capable of impacting all memory cells (TCM, TTM and TEM). Importantly, it has been shown
that both drugs have different capacity to inhibit cell-associated HDAC activity [43]. Thus, it is
tempting to speculate that differential expression of HDAC isoforms within different CD4+ T
cell subsets could be associated to their intrinsic capability to reactivate latent HIV. In concor-
dance with our results, in a recent study, cells treated with Panobinostatt that reactivated HIV
appeared to be long-lived whereas Romidepsin appeared to reactivate HIV in shorter life span
cells [45]. This study calculated the life span of cells that reactivated HIV in vivo using mathe-
matical models. Consistently, Banga et al. showed that Panobinostat was slightly more robust
than Romidepsin at reactivating HIV in isolated resting memory CD4+ T cells, a fraction
enriched in long-lived central memory cells [25]. We also observed that TCM and TNA cells
have the broadest susceptibility to the different families of LRAs, and Ingenol was extremely
efficient at reactivating TNA, TSCM, TCM and TTM but did not show a significant effect on TEM
cells. In this regard, a recent study determined that the majority of cells expressing HIV-1
RNA in the presence of Ingenol had a TCM/TTM and TEM phenotype [31]. Additionally, while
the TNA subpopulation has not traditionally been considered as a cellular HIV reservoir, this
subset has been recently described as a large inducible cell reservoir of both latent and replica-
tion competent virus at levels similar observed in TCM [46], which is in concordance with our
results. One of the main limitations of the present study is our inability to detect p24 in most
of the cell subsets. In general, there was an agreement between the frequency of cells expressing
HIV-1 RNA and cells producing p24. However, we were only able to detect p24 in the whole
CD4+ T cell population and in TCM cells. This is not the result of a poor sensitivity of the RNA
FISH/flow method (10–20 positive cells per million), instead it might be explained by the low
absolute number of HIV-RNA+ cells observed within subsets that were represented in small
frequencies as i.e. TSCM, TTM, TEM and TTD (all below 30%).
We observed that long-lived cells such as TCM or TSCM, previously defined to be important
in the long-term maintenance of HIV reservoirs in patients [19,20], have different
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susceptibilities to the LRAs tested. For instance, TSCM were poorly reactivated with most
drugs. Only the combination of Panobinostat and Bryostatin-1, and to a lesser extent Ingenol,
were able to significantly increase the proportion of HIV-1 RNA+ cells in this subset. This find-
ing highlights the difficulty to identify LRAs with a mechanism of action broad enough to reac-
tivate latent HIV present in all HIV-infected cells. Moreover, the lack of effect of the LRAs on
TSCM cells is a concern, since viral recrudescence from these long-lived cells might significantly
preclude the in vivo long-term efficacy of LRAs tested in clinical trials. Thus, our results have
important implications for rational design of therapies aimed at reversing HIV latency; the
knowledge of the individual mechanisms that lead to viral reactivation in the population of
cells that encompass the latent HIV reservoir will help with the development of LRAs with
which to impact HIV persistence.
Importantly, we found that the combination of Romidepsin and Ingenol induced the high-
est frequency of HIV-1 RNA+ cells, even more than the positive control with PMA and Iono-
mycin, and this finding was consistent in all tested samples. To our knowledge, the
combination of Romidepsin plus Ingenol has never been explored before in this setting. The
independent mechanism of action of both drugs is most likely the responsible for the high
number of HIV-1 RNA+ cells detected. This argument is supported by the observation that the
combination of both drugs does not induce higher number of HIV-1 RNA molecules per cell
(mean fluorescence intensity) (S5B Fig), instead it induces a broader spectrum of cells that are
able to express HIV-1 RNA upon viral reactivation. Moreover, the synergistic effect was partic-
ularly evident in the TCM and TTM memory subsets, indicating that the differentiation or mat-
uration status of the cells may be a critical determinant for a successful viral reactivation with
the different LRAs. In this sense, it has been recently reported that CD4+ T cell subsets have
distinct transcriptional profiles that are related to the level of HIV-1 infection and might mod-
ulate the response to external stimulus [47]. We also determined a robust antagonistic effect
(89% in whole CD4+ T cells) when Panobinostat and Ingenol were combined. This is in agree-
ment with the study presented by Larragoite et al. [48], in which they showed that the co-treat-
ment with both drugs inhibited the reactivation of HIV in an ex vivo model of resting CD4+ T
cells isolated from aviremic patients, despite a synergistic relationship was demonstrated in an
in vitro latency cell model (J-Lat 10.6). The authors speculate that the inhibition induced by
Panobinostat of the chaperone heat shock protein 90 (Hsp90), which is directly involved in the
reversion of HIV-1 latency by Ingenol [49], might reduce the activation of the NF-kB pathway
caused by the PKC agonist. This could explain the antagonistic effect observed when these two
drugs are combined. In addition, it has also been observed that Panobinostat induces latency
reversal by an Hsp90 independent way [48]. Further, these results manifest again the existing
discrepancies between latently infected T cell lines and primary cell models of HIV-1 latency
[32].
In conclusion, this study highlights the inability of current LRAs to fully reactivate HIV hid-
den in diverse cellular reservoirs. The identification of compounds with a broader reactivation
capacity or the use of complementary drugs with different mechanisms of action will be
needed to reactivate latent virus present in different cell types, where more likely diverse cellu-
lar pathways are implicated in silencing HIV.
Materials and methods
Ethics statement
PBMCs (peripheral blood mononuclear cells) from adults (>18 years old) HIV-1-infected
patients were obtained from the HIV unit of the Hospital Universitari Vall d’Hebron in Barce-
lona, Spain. Written informed consent was provided by all patients who participated in this
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study, and the protocols used were approved by the Comitè d’E`tica d’Investigacio´ Clı´nica
(Institutional Review Board numbers 39–2016 and 196–2015) of the Hospital Universitari Vall
d’Hebron, Barcelona, Spain. All samples were obtained only from adults and were totally
anonymous and untraceable.
Study samples
Samples from HIV-1-infected patients under ART with CD4+ T cell counts higher than 100
cells/mm3 and viral load <50 cop/ml for a mean (min-max) of 3 (1–6.5) years were recruited
in the HIV unit of the Hospital Universitari Vall d’Hebron in Barcelona (Spain) and were
included in this study. Information on plasma viral loads, CD4+ T cell counts, and time on
ART for treated patients is summarized in S1 Table.
Cells
Fresh PBMCs were obtained from a whole blood donation (400ml) from HIV-infected
patients by Ficoll-Paque density gradient centrifugation and cells were immediately used with-
out previous cryopreservation. Isolated CD4+ T cells (MagniSort Human CD4+ T Cell Enrich-
ment; eBioscience) were cultured in RPMI medium (Gibco) supplemented with 10% fetal
bovine serum (FBS; Gibco), 100 μg/ml streptomycin (Capricorn Scientific) and 100 U/ml peni-
cillin (Capricorn Scientific), (R10). The human latently infected cell line J-Lat (clone 10.6) was
obtained through the NIH AIDS Reagent Program from Eric Verdin [50]; cells were grown in
R10 and maintained at 37˚C in a 5% CO2 incubator.
Viral reactivation with latency reversal agents
Isolated CD4+ T cells were stimulated during 22h with latency reversal agents (LRAs) at the
following concentrations: 40 nM Romidepsin (Selleckchem), 30 nM Panobinostat (Selleck-
chem), 1 μM JQ1 (Sigma-Aldrich), 100 nM Ingenol-3-angelate (Sigma-Aldrich), 10 nM Bryos-
tatin-1 (Tocris Bioscience), the positive control (PMA 81 nM plus Ionomycin 1 μM, both from
Abcam), or the negative control (media alone, R10). Drugs were used at concentrations previ-
ously shown to be effective at reversing latency in studies performed in CD4+ T cells from
HIV-infected individuals as well as studies performed in latency models in vitro [23,32,33]. All
compounds were reconstituted in DMSO at the maximum concentration of 0.006%. More-
over, in order to prevent cell death induced by the reactivation of HIV and to evaluate the reac-
tivation effect without confounding variables, cells were pre-treated with a pan-caspase
inhibitor named Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl
ketone, Selleckchem) [51,52]. Q-VD-OPh is a potent inhibitor for caspases 1, 3, 8 and 9, which
are involved in the intrinsic and extrinsic apoptotic pathways, inhibiting consequently the spe-
cific cell death induced by HIV [53–56]. In all experiments, cells were treated with 10 μM of
Q-VD-OPh for at least 2h prior to the addition of the latency reversal agents.
Detection of viral reactivation and cell death by the IncuCyte Live-Cell
analysis technology
HIV reactivation and toxicity effects induced by the different LRAs were longitudinally and
exhaustively determined in the latently infected cell line J-Lat 10.6. Viral reactivation and cell
death was monitored using the IncuCyte ZOOM live cell imaging system (Essen Bioscience).
The latently infected cell line J-Lat contains integrated but transcriptionally latent HIV provi-
ruses, in which the reporter gene GFP replaces the nef coding sequence [50]. GFP was used to
measure viral reactivation and the apoptotic marker Annexin V (Essen Bioscience) was used
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to determine cell death induced by the drugs or by cytopathic effect. Briefly, cells were pre-
treated with the pan-caspase inhibitor Q-VD-OPh for at least 2h and then seeded at 25.000
cells per well in a 96 well plate. Single LRA or combination of different families of LRAs were
added to the corresponding well and Annexin V reagent (1:200) was immediately added on
cells, with a final well volume of 100μl. Images were captured every hour for 48h from 2 inde-
pendent wells per condition. Green (HIV expression) and red (Annexin V) object counts per
well (1/mm2) were quantified at each time point and values were normalized to the confluence
of each well.
Drug toxicity assays in CD4+ T cells
Cell toxicity was assessed for single drugs and the combination of different LRA families in pre-
viously isolated CD4+ T cells from three independent uninfected donors. CD4+ T cells were
pre-incubated with the pan-caspase inhibitor Q-VD-OPh for 2h. Afterwards, CD4+ T cells
(200,000 cells per well) were incubated for 22h with the compounds. Then, cells were stained
with the apoptotic marker Annexin V (PE, Biolegend) and a viability dye (LIVE/DEAD fixable
Violet Dead Cell Stain kit, Invitrogen) in order to identify the following stages of cell death: live
cells (Annexin V- Viability-), early apoptotic cells (Annexin V+ Viability-), late apoptotic+
necrotic cells (Annexin V+ Viability+) and total cell death (Annexin V- Viability+). In addition,
different surface markers, including CD3 (Pe-Cy7, BD Biosciences), CD4 (AF700, BD Biosci-
ences), CD45RO (BV605, Biolegend) and CD27 (FITC, Biolegend), were used to identify
drug toxicity induced in the different CD4+ T cell subpopulations. The CD4+ T cell subsets
were identified as follows: Naïve (TNA) and Stem Cell Memory (TSCM) (CD3+CD4+CD27+
CD45RO-), Central (TCM) and Transitional Memory (TTM) (CD3
+CD4+CD27+ CD45RO+),
Effector Memory (TEM) (CD3
+CD4+CD27- CD45RO+) and Terminally Differentiated cells
(TTD) (CD3
+CD4+CD27- CD45RO-).
RNA FISH/flow assay of single cells expressing HIV-1 RNA transcripts and
p24 protein after viral reactivation
PBMCs from nine ART-treated HIV-infected patients were obtained from a whole blood
donation (400ml) and CD4+ T cells were isolated by negative selection using magnetic beads
(MagniSort Human CD4+ T Cell Enrichment; eBioscience). A total of 13 conditions were
assayed per patient and at least 6x106 of freshly-isolated CD4+ T cells were subjected to viral
reactivation per condition, which included the individual LRAs, the combination of 2 different
families, and the positive and negative controls. Prior to viral reactivation, cells were pre-incu-
bated with the pan-caspase inhibitor Q-VD-OPh for 2h. In order to block new rounds of viral
infection during viral reactivation, cells were treated with LRAs in the presence of Raltegravir
(1uM) during 22h. Afterwards, cells were subjected to the RNA FISH/flow protocol for the
detection of HIV transcripts and the viral protein p24 following the manufacturer’s instruc-
tions (Human PrimeFlow RNA Assay; eBioscience) with some modifications, as previously
described [30]. Briefly, PBMCs were stained with antibodies against cell surface markers and
viability dye. Cells will be then fixed, permeabilized, and intracellularly stained for detection of
the viral p24 protein. After an additional fixation step, cells will be ready for 3h of probes
hybridization at 40±1˚C with a high-sensitivity target-specific set of 50 probes spanning the
whole Gag-Pol HIV mRNA sequence (bases 1165 to 4402 of the HXB2 consensus genome).
The cells will be then subjected to different amplification steps (sequential 2h incubations at
40˚C). Finally, multiple label probes will be hybridized with the specific amplifiers (1 h
at 40˚C) and samples will be run on an LSR Fortessa four-laser flow cytometer (Becton
Dickinson).
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In these experiments, to identify the different CD4+ T cell subpopulations expressing HIV-
1 RNA and the viral protein p24, the following antibodies were used for cell surface staining:
CD3 (AF700, Biolegend), CCR7 (Pe-CF594, BD Biosciences), CD27 (FITC, BD Biosciences),
CD45RO (BV605, Biolegend) and CD95 (Pe-Cy5, BD Biosciences). The CD4+ T cell subset
phenotypes were identified as follows: TNA (CD3
+ CCR7+ CD45RO- CD27+ CD95-); TSCM
(CD3+ CCR7+ CD45RO- CD27+ CD95+); TCM (CD3
+ CCR7+ CD45RO+); TEM (CD3
+ CCR7-
CD45RO+ CD27-); TTM (CD3
+ CCR7- CD45RO+ CD27+) and TTD (CD3
+ CCR7- CD45RO-).
The surface marker CD32 (Pe-Cy7, Biolegend) was also included in the analysis. The expres-
sion of HIV-1 RNA transcripts was analyzed with target-specific AF647-labelled probes, and
the expression of the Gag p24 viral protein was detected with a PE-anti-p24 antibody (clone
KC57 RD1; Beckman Coulter). Cell viability was determined using a violet viability dye for
flow cytometry (LIVE/DEAD fixable Violet Dead Cell Stain kit, Invitrogen). All values of
HIV-1 RNA were normalized to the negative control (R10) corresponding to the non-reacti-
vated cells from each patient.
Sensitivity of the assay at detecting productive HIV-infected cells
To test the sensitivity of the assay at detecting cells expressing both HIV-1 RNA and p24, pri-
mary infected CD4+ T cells from HIV-infected patients were expanded. We used the same pro-
tocol described for the qVOA assay [30], and the positive wells were mixed up and diluted into
uninfected cells at six different ratios. Samples were then subjected to the RNA FISH-flow
assay. The predictive curve was determined by the basal expression of HIV-1 RNA and p24
and the subsequent theoretical values of the serial dilutions. The infection rate (experimental
curve of percent HIV RNA+p24+ cells) was calculated by using the values obtained with the
RNA FISH-flow assay. Linear regression was computed to determine the linearity of the rela-
tionship between the predicted and experimental values of the assay.
Proviral HIV-DNA quantification by qPCR
CD4+ T cells were isolated by negative selection as mentioned above. For proviral quantifica-
tion, 1 million CD4+ T cells were immediately lysed in a Proteinase K-containing lysis buffer
(at 55˚C over-night and at 95˚C for 5 minutes). Cell lysates were subjected to HIV-DNA quan-
tification by qPCR using primers and probes specific for the 1-LTR HIV region (LTR forward
5’-TTAAGCCTCAATAAAGCTTGCC-3’, LTR reverse 5’-GTTCGGGCGCCACTGCTAG-3’
and probe 5’ /56-FAM/CCAGAGTCA/ZEN/CACAACAGACGGGCA/31ABkFQ/ 3’), as pre-
viously described [57]. CCR5 gene was used for cell input normalization. Samples were ana-
lyzed in an Applied Biosystems 7000 Real-Time PCR System.
Statistical analysis
Statistical analyses were performed using the Prism software (GraphPad) version 6.01. Data
are shown as the median and the min-max rank. Comparisons among the frequency of HIV-1
RNA expressing cells between unstimulated control (R10) and viral-reactivated conditions
were performed using the Wilcoxon signed rank test. For correlations, Spearman’s correlation
coefficient was calculated. To test the linearity of the assay, a linear regression was performed.
A Friedman ANOVA test was used to compare the frequency of HIV-1 RNA+ cells induced by
Romidepsin plus Ingenol with the levels induced by the other drugs in the different CD4+ T
cell subsets, with corrected p-values for multiple comparisons (Dunn’s test). A p value of
<0.05 was considered statistically significant. Synergies and antagonisms effects between
drugs were calculated using the Bliss independence model (values <-0.09 were considered as
highly antagonistic, values > 0.09 were considered as highly synergistic. Intermediate values
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between 0.09 and -0.09 were considered to have an additive effect). Data are presented as the
difference between the observed and the predicted responses of each combination (Δfaxy =
faxy,O—faxy,P), where faxy,O is the observed fraction affected and faxy,P is the predicted fraction
affected. The faxy,P is calculated as faxy,P = fax+fay−(fax�fay) where fax is the fraction affected by
drug X and fay is the fraction affected by drug Y [33].
Supporting information
S1 Fig. Q-VD-OPh inhibits the apoptosis of viral-reactivated cells. The effect of the pan-cas-
pase inhibitor Q-VD-OPh on the detection of viral-reactivated cells was evaluated in isolated
CD4+ T cells from ART-suppressed HIV-infected patients and in the latently infected cell line
J-Lat (clone 10.6). A. GFP expression in J-Lat cells was monitored by the IncuCyte ZOOM live
cell imaging system (Essen Bioscience) every hour for 50 hours after the addition of Panobino-
stat (30 nM) with or without Q-VD-OPh. B. CD4+ T cells were reactivated with Panobinostat
(PNB, 30 nM) in the presence of Q-VD-OPh (10μM). Control cultures were treated with
media alone (R10) or treated with media and Panobinostat (PNB). Copies of HIV-1 RNA per
million CD4+ T cells were quantified in samples from 6 HIV+ patients by qPCR. Open circles
show values under the limit of detection. Fold-change (FC) of viral reactivation is compared
between conditions, but only in those where HIV-1 RNA was detected.
(TIF)
S2 Fig. Detection of HIV-1 RNA and p24 after viral reactivation by the RNA FISH/flow
assay in J-Lat cells. Cells were incubated for 22h with medium alone (R10), Romidepsin
(RMD, 40 nM) or Romidepsin (40 nM) plus Ingenol (ING, 100 nM). Cells were then subjected
to the RNA FISH/flow protocol and the proportion of HIV-1 RNA+ and p24+ (A) and HIV-1
RNA+ and GFP+ (B) cells was determined by flow cytometry. A flow cytometry plot for each
condition is shown. C. Infection of primary CD4+ T cells from HIV-infected patients were
expanded in vitro, and infected cells were diluted with uninfected cells to perform the quantifi-
cation of predicted (blue symbols) versus experimental (orange symbols) values of HIV-1
RNA+ p24+ expression measured by the RNA FISH/flow assay. Assay linearity was assessed by
linear regression.
(TIF)
S3 Fig. Drug toxicities in CD4+ T cells and in CD4+ T cell subpopulations. Isolated CD4+ T
cells from 3 uninfected donors were incubated with the different drugs for 22 hours (40 nM
Romidepsin, 30 nM Panobinostat, 1 μM JQ1, 100 nM Ingenol, 10 nM Bryostatin-1, 81 nM
PMA plus 1 μM Ionomycin or media alone) and cell death was evaluated by flow cytometry in
the whole CD4+ T cell population and in the different CD4+ T cell subsets. Cell subsets were
identified as Naïve and Stem Cell Memory (TNA/TSCM) (CD3+CD4+CD27+ CD45RO-), Central
and Transitional Memory (TCM/TTM) (CD3
+CD4+CD27+ CD45RO+), Effector Memory (TEM)
(CD3+CD4+CD27- CD45RO+) and Terminally Differentiated cells (TTD) (CD3
+CD4+CD27-
CD45 RO-). Cells were stained with the apoptotic marker Annexin V and a viability dye. A. Gat-
ing strategy used to identify the following stages of cell death: live cells (Annexin V- Viability-),
early apoptotic cells (Annexin V+ Viability-), late apoptotic+necrotic cells (Annexin V+ Viabil-
ity+) and total cell death (Annexin V- Viability+). B-C. Percentage of cell death and apoptosis
induced by the different single LRAs and their combinations in total CD4+ T cell population in
presence (B) or absence (C) of the pan-caspase inhibitor Q-VD-OPh. D-E. Drug toxicities in
different CD4+ T cell subpopulations, including TNA/TSCM, TCM/TTM, TEM and TTD in presence
(D) or in absence (E) of Q-VD-OPh. Median values and min-max ranks are represented in pan-
els B-E. In all panels, total dead cells are represented in green, early apoptosis is shown in orange
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and late apoptosis and necrosis is represented in blue.
(TIF)
S4 Fig. Detection by the RNA FISH/flow assay of cells expressing HIV-RNA and p24 after
viral reactivation in primary CD4+ T cells from HIV-infected patients. Isolated CD4+ T
cells from 9 ART-suppressed HIV-infected individuals were reactivated with different LRAs
for 22h and subjected to the RNA FISH/flow assay to analyze the frequency of cells expressing
HIV-RNA and the viral protein p24. A. Gating strategy used to analyze HIV reactivation in
CD4+ T cells and in the different CD4+ T cells subsets. B. Calculation of synergistic, antagonis-
tic or additive effects in CD4+ T cells for the different combination of LRA families using the
Bliss independence model. C. Percentage of cells expressing CD32dim in HIV-1 RNA+ and
HIV-1 RNA- CD4+ T cells after treatment with the different LRAs plotted by Tukey boxplot.
Medians of 9 independent experiments are shown in panels B and C. D. Correlation between
the proportion of HIV-1 RNA+ cells per million cells, and the proportion of cells HIV-1 RNA+
expressing the viral protein p24. Spearman’s nonparametric correlation coefficient and associ-
ated P value are shown.
(TIF)
S5 Fig. A. Percentage of different CD4+ T cell subpopulations after treatment with the
LRAs. Percentage of each subset (TNA, TSCM, TCM, TTM, TEM and TTD) was determined after
22 hours of culture with single or combination of LRAs (40 nM Romidepsin, 30 nM Panobino-
stat, 1 μM JQ1, 100 nM Ingenol, 10 nM Bryostatin-1, 81 nM PMA plus 1 μM Ionomycin or
media alone) by flow cytometry. Dashed red line show the effect at 22h for the negative con-
trol, R10. Asterisks denote statistical significance compared with the negative control (R10)
using a Friedman test followed by Dunn’s post hoc tests. �p<0.05, ��p<0.01. B. Mean Fluores-
cence Intensity (MFI) of HIV-1 RNA+ cells after viral reactivation with Romidepsin (RMD),
Ingenol (ING) and the combination of Romidepsin with Ingenol (RMD+ING).
(TIF)
S6 Fig. Heatmaps and drug synergies in viral-reactivated CD4+ T cell subsets. A-B. Sum-
mary heatmaps of the potency of single LRAs (A) and their combinations (B) at increasing the
proportion of HIV-1 RNA+ cells in the different CD4+ T cell subpopulations. C. Analysis of
the interactions between LRAs, using the Bliss independence model, is shown for each CD4+ T
cell subset. D. Interaction between LRAs on the ability to increase the proportion of p24+ cells
within HIV-1 RNA+ cells in the TCM subset are shown for each patient. Medians and min to
max ranks are represented in panels C and D.
(TIF)
S1 Table. Clinical data of patients included in the study. Patient ID, time since HIV diagno-
sis, CD4 cell count, % of CD4, viral load (cop/ml), time on suppressive ART and HAART regi-
men were included.
(PDF)
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